rel perform spin-off
report discuss
compar view abbott
recommend buy rate
compani tp
abbott
base abbott
perform
upsid potenti
base jan
abbvi upsid potenti increas due
fall stock price
abbott roa roi roe stood
respect ytd
perform stock
perform
abbvi roa roi roe
respect ytd
perform stock
perform
expect abbott revenu grow
revenu grow
estim abbott
adjust ep
adjust ep
recommend buy rate
abbott upsid
potenti abbott
due declin stock
price abbott hold better
posit invest abbvi
consid futur growth prospect
compani
compani nameabbott laboratoriesabbvi inctickerabtabbvcurr stock ratingbuybuylast year ratingbuybuyindustri viewoverweightoverweightpositivepositivepric year jan upsid week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm abbott vs februari
engag discoveri develop manufactur
sale rang healthcar product year abbott
oper four segment establish pharmaceut product
diagnost product nutrit product vascular product
abbott perform strong due growth across
segment strong pipelin receiv approv
product alongsid achiev clinic trial mileston last quarter
abbott revenu increas due growth
diagnost busi report ep
adjust ep increas abbott gener
strong oper cash flow paid debt
abbott return sharehold form dividend
decemb announc increas quarterli common
octob abbott receiv fda approv heartmat left
ventricular assist devic destin long-term use therapi januari
abbott announc fda approv tacticath contact forc
ablat cathet sensor enabl new cathet design help
physician accur effect treat atrial fibril form
abbott freestyl libr achiev rapid market uptak y/i
increas sale expect continu gain
abbott stock perform strong due strong growth
busi stock volatil till august later show upward
trend surg decemb low
stock februari
expect perform well due strong product pipelin
recent present posit clinic result coapt studi
support efficaci mitraclip expect boost uptak
product top-lin contribut expect stock reach
revenu growth expect
launch independ biopharmaceut compani
spin-off januari bring togeth
stabil resourc commerci capabl global pharmaceut
compani focu cultur agil biotech januari
abbott sharehold receiv one share common stock everi
one share abbott common stock held close busi
abbvi revenu grew due strong growth
oncolog product imbruvica humira ep increas
adjust ep increas
deep pipelin consist sever interest late-stag
candid success seek approv product like
imbruvica venclexta mavyret contribut
growth busi expect two approv
gener revenu compani
rova-t ad portfolio follow acquisit
stemcentrx june failur triniti clinic hold
taho rais skeptic rova-t potenti brought
question viabil stemcentrx deal
abbvi stock perform declin dip
novemb stock surg januari
downward trend sinc march due coupl pipelin setback well
concern biosimilar competit blockbust drug humira eu
abbvi humira perform well base strong demand trend
despit new competit competit europ erod humira
revenu expect growth revenu expect
stock reach base forward price-to-earnings multipl
adjust ep
creat breakthrough product diagnost medic
devic nutrit brand gener pharmaceut
year abbvi inc research-bas compani
spin-off sinc januari
abbott oper four segment establish
product diagnost product nutrit product vascular product
offer product variou categori includ humira oncolog
metabolics/hormon product endocrinolog product product
includ duopa duodopa anesthesia product zinbryta
abbott diagnost medic devic busi revenu increas y/i
contribut growth busi wherea major
revenu gener humira strong product
pipelin like imbruvica venclexta mavyret also gener
revenu compani
abbott diagnost busi increas led
inclus aler acquisit abbott continu see strong
adopt alin point-of-car diagnost system year
abbott medic devic busi st jude busi
abbott acquir increas
medic devic segment diabet busi strong growth
revenu due rapid uptak freestyl libr
abbott electrophysiolog growth led strong perform cardiac
map ablat cathet januari abbott announc
fda approv tacticath contact forc ablat cathet sensor
enabl new cathet design help physician accur
abbvi humira sale increas gener
total revenu year humira face declin sale
outsid due direct biosimilar competit certain intern
howev strong product pipelin
contribut growth compani net revenu
hematolog oncolog portfolio increas
imbruvica sale increas venclexta sale reach
hcv product mavyret sale increas
abbott diagnost medic devic segment growth driver
compani two segment nutrit establish
pharmaceut busi also contribut growth
gener free cash flow compani
wherea sale depend humira contribut
sale compani face biosimilar competit outsid
acquir stemcentrx deal complet failur
studi drug stop drug meet
howev abbvi hematolog oncolog portfolio product growth
acceler compani still shift relianc
humira gener strong growth futur
abbott revenu increas sinc spin-off pharma
busi name sinc revenu increas
reach
abbott growth driver diagnost medic devic busi
expect revenu reach abbvi core growth driver
humira led compani grow fast pace expect
abbvi revenu reach
abbott gross margin revenu ttm basi
gross margin revenu ttm basi gener
gross margin compar abbott gross margin
favor impact reduct humira royalti expens off-set
imbruvica profit share arrang foreign exchang wherea
abbott gross margin reflect improv variou busi
acquisit made compani
abbott oper margin ttm oper margin
ttm basi abbott oper expens increas due
acquisit aler invest busi wherea
abbvi oper expens increas due contribut variou charit
institut invest pipelin howev gener better
oper margin compar abbott
abbott net margin ttm basi abbvi net margin
ttm basi abbott net earn
net earn show earn
strong manag expens well compar abbott
abbott ep declin sinc spin-off independ compani
abbott ep declin compar
abbott ep due variou acquisit
increas expens expect ep reach
adjust ep reach forward price-to-earnings multipl abbott
wherea ep increas compar
earn increas fast pace spin-off
show huge growth busi expect ep reach
adjust ep reach forward price-to-earnings multipl
sinc stock price outperform due growth
busi fast pace howev stock drop
due fear regard humira sale failur stemcentrx acquisit
wherea abbott stock price under-perform till
show huge growth later abbott stock price surg due
strong growth medic devic diagnost busi
shown better growth revenu earn give better
dividend yield compar abbott revenu earn
dividend yield howev concern near futur
revenu depend humira lose patent come
year alreadi face competit europ
wherea abbott medic devic diagnost segment growth
driver gener busi strong portfolio product
recommend buy rate compani tp
incom statement forecast
non- reconcili
per share item ratio
product perform develop
valuat consensu perform
total revenu increas y/i month perform
upgrad rate buy abbott tp
previous provid upsid potenti
deriv estim base
forward price-to-earnings multipl ep
estim top-lin revenu grow
estim base follow factor strong
growth across segment acquisit aler inc new
product launch quarter strong pipelin
advanc across portfolio
abbott deliv strong result due strong growth across
segment continu develop pipelin total
revenu increas sale grew
organ basi adjust ep
gaap ep
diagnost segment sale grew quarter alin
sell highli differenti instrument achiev
acceler growth strong competit win rate europ
alin instrument placement thu far
come share captur diagnost sale
driven cardiometabol test
establish epd sale led double-digit
growth sever geographi includ russia china
nutrit sale increas quarter led strong
perform intern busi
medic devic sale grew quarter led double-
digit growth electrophysiolog structur heart diabet
compani nameabbott laboratoriestickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth abbott vs februari
diabet anoth area abt technolog
 receiv fda approv sensor
shorter one-hour warmup make libr longest
obtain ce mark freestyl libr system freestyl
libr user across globe
juli us initi pivot trial tendyn devic
design replac damag mitral heart valv without
need open heart surgeri
also receiv fda approv third gener
version mitraclip market lead devic repair
septemb announc result landmark coapt trial
demonstr mitraclip improv surviv clinic
outcom patient function mitral regurgit
preval form condit
current price-to-earnings trade
price-to-earnings trail sinc
june due strong growth stock price price-to-earnings
june averag price-to-earnings
expect forward price-to-earnings multipl
recommend buy rate base month perform
acquisit aler inc strong develop pipelin
across portfolio
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date oct last split factor new per last split date jan inform abbott vs februari
incom statement item total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli abbott vs februari
 defer incom prepaid current total current net properti plant equiti intang defer incom long-term total non-curr total short-term account tax accru current total current long-term defer tax pension minor long-term total non-curr total addit paid-in retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli abbott vs februari
net cash oper activ period increas due higher segment
oper earn continu improv work capit manag time pension
contribut lower acquisition-rel expens
net cash use invest activ period compar
net cash use financ activ period compar
depreci invest loss stock base chang work account prepaid account incom tax work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt prefer stock common stock dividend financ net cash provid use financ effect exchang rate net chang begin end total revenu increas
compar
increas
rapid diagnost
acquir late last
year therefor
includ organ sale
sale
abbott deliv strong result due strong growth across segment
acquisit aler inc close
total revenu increas compar
organ sale increas net sale growth
exclud impact foreign exchang driven growth
abbott busi segment acquisit aler inc aler close
total revenu increas compar
increas categori reflect growth abbott
diabet busi partial off-set sale abbott medic optic
amo busi johnson johnson double-digit growth diabet
led freestyl libr abbott sensor-bas continu glucos monitor
cgm system remov need routin fingerstick peopl
total revenu increas compar
total intern revenu increas
compar
rapid diagnost acquir late last year therefor
includ organ sale growth result achiev sale
exchang unfavor y/i impact sale
quarter us dollar strengthen versu sever currenc result
larger unfavor impact result quarter
cog increas compar
amort intang asset increas
compar
gross margin increas compar
increas primarili reflect favor comparison versu prior year
includ inventori step-up amort relat st jude medic
acquisit increas also reflect margin improv variou busi
includ diabet cardiovascular neuromodul
 expens increas compar
increas due addit acquir aler
busi well higher spend area cardiovascular
compar
sg expens increas compar
increas due addit acquir aler
busi well higher spend drive continu growth market
expans variou busi partial off-set lower acquisition-rel
gaap ep decreas
compar
total oper incom increas compar
interest expens decreas
compar effect tax rate
compar
net incom decreas compar
non-gaap net incom increas
compar
gaap ep decreas compar
non-gaap ep increas compar
period total revenu increas
compar period total
revenu increas compar
period total intern revenu increas
compar increas
revenu due strong growth across busi segment
period cog increas
compar period amort
intang asset increas compar
period expens increas
compar nine month period expens
cardiovascular neuromodul product segment
diagnost product segment nutrit
product segment establish pharmaceut product
period sg expens increas
compar increas due addit
acquir aler busi well higher spend drive continu growth
market expans variou busi partial off-set lower acquisition-
period oper expens increas
compar period
oper incom compar
period interest expens flat
compar prior-year period effect tax rate declin
compar
period net incom increas
compar period adjust net
incom increas compar
period ep increas
compar period non-gaap ep
increas compar
increas
compar
increas
compar
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic total revenu
report segment increas compar
total revenu increas
compar segment revenu
total revenu follow
decreas
report basi
compar
includ unfavor
effect foreign
sale emerg
market increas due
india china
establish pharmaceut sale decreas report
basi compar includ
unfavor effect foreign exchang total revenu increas
organ basi period total revenu
increas compar
sale growth quarter neg impact comparison
versu sale higher normal due channel
restock across market implement new tax system
total revenu key emerg market establish
pharmaceut product increas
period emerg market establish pharmaceut
product busi includ india russia brazil china along sever
market repres attract long-term growth
opportun abbott brand gener product portfolio sale
emerg market increas due double-digit growth across sever
geographi includ india china
total revenu market increas
period compar
world-wide revenu nutrit product increas
report basi compar
sale includ unfavor effect foreign exchang
increas organ basi
total revenu key
emerg market
increas
period
increas
compar previou
year quarter
total revenu increas
compar previou year quarter period
total revenu increas
total intern revenu increas
compar previou year quarter total intern revenu
increas
world-wide pediatr nutrit revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
organ basi period total revenu increas
compar prior-year period
total revenu increas
compar previou year quarter period
total revenu increas
compar prior-year period
total intern revenu increas report basi
compar previou year quarter
period total revenu increas
compar prior-year period
strong perform quarter led market growth
double-digit growth asia latin america
total revenu increas compar
previou year quarter includ unfavor effect foreign
exchang increas organ basi total revenu
increas compar prior-year period
total revenu declin
compar previou year quarter period total
revenu increas compar
prior-year period
total intern revenu increas report basi
compar previou year quarter
month period total revenu increas
compar prior-year period
total revenu
increas
compar previou
year quarter
compar
previou year
revenu increas
compar
sale perform led strong growth ensur abbott market-
lead complet balanc nutrit brand glucerna abbott
market-lead diabetes-specif nutrit brand sale neg
impact abbott wind non-cor product line
increas
compar
previou year
world-wide diagnost revenu increas
compar revenu increas
organ basi period total revenu increas
compar
diagnost product revenu increas
compar previou year quarter
period total revenu increas
compar prior-year period
diagnost product intern revenu increas
compar previou year quarter
period total intern revenu increas
compar prior-year period
laboratori diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
organ basi period total revenu increas
compar prior-year period
increas
compar previou
year quarter
growth laboratori diagnost revenu quarter
due above-market growth intern total
revenu increas
compar previou year quarter period total
revenu increas compar
previou year quarter
point diagnost
revenu increas
compar
previou year
world-wide molecular diagnost revenu increas
compar previou year quarter world-wide
sale led growth infecti diseas test
period total revenu increas compar
prior-year period
total revenu increas
compar previou year quarter period
total revenu decreas compar
point diagnost
point diagnost revenu increas
compar previou year quarter includ unfavor
effect foreign exchang increas organ basi due
strong intern growth abbott i-stat handheld system
period total revenu increas
compar prior year period
total revenu increas
compar previou year quarter period total
revenu declin
point diagnost
revenu
period
total intern revenu increas
compar previou year quarter period
total intern revenu increas
compar prior-year period
report
basi
compar
previou year
diagnost revenu
month period total revenu
period total intern
revenu
period increas led cardiometabol test
world-wide medic devic sale increas report basi
compar previou year quarter
organ basi sale increas period total
revenu increas compar prior-
year period
medic devic revenu increas
compar previou year quarter
period total revenu increas
compar prior-year period
medic devic intern revenu increas
compar previou year quarter
period total intern revenu increas
compar prior-year period
cardiovascular neuromodul
cardiovascular neuromodul revenu increas
compar previou year quarter
month period total revenu increas
compar prior-year period
electrophysiolog revenu increas
compar previou year quarter period
total revenu increas total revenu
 increas total intern
revenu increas growth led
strong perform cardiac map ablat cathet well
strong growth abbott confirm rxtm insert cardiac monitor icm
structur heart revenu increas
compar previou year quarter period total
revenu increas total revenu
 increas total intern revenu
increas growth structur heart
driven sever product area across abbott broad portfolio includ
amplatzertm pfo occlud mitraclip abbott market-lead devic
minim invas treatment mitral regurgit
diabet revenu increas
compar previou year quarter period total
revenu increas compar prior-year
period total revenu increas
compar previou year quarter total intern revenu
increas compar previou year
quarter growth led rapid market uptak freestyl libr
cardiovascular
revenu increas
compar
previou year
revenu increas
compar
previou year
 fda approv
minim invas
obtain ce mark
juli abbott receiv fda approv third-gener version
minim invas mitraclip heart valv repair devic new version
includ design advanc simplifi procedur enabl
patient treat mitraclip
septemb abbott announc posit clinic result landmark
coapt studi demonstr mitraclip improv surviv
clinic outcom select patient function mitral regurgit
coapt studi data submit fda support consider
expand indic mitraclip
quarter abbott receiv fda approv freestyl libr
day sensor longest last glucos wearabl sensor avail
octob abbott obtain ce mark freestyl libr system next-
octob abbott announc heartmat left ventricular assist
devic lvad receiv fda approv destin therapi
peopl live advanc heart failur approv physician
offer heartmat system patient elig transplant
live devic rest live
novemb abbott announc launch new drg invis trial
approv fda receiv ce mark europ
patient find adequ pain relief drg therapi
abbott proclaim drg system implant empow
manag pain familiar consum technolog
abbott project adjust ep
ep
abbott expect organ sale growth rang expect
adjust gross margin ratio sale adjust
sale adjust sg expens sale
abbott forecast net specifi item per share
expens charg associ cost reduct initi
expect ep non-gaap ep
would
abbott forecast specifi item primarili relat
intang amort acquisition-rel expens cost reduct
initi expens
adjust ep
ep
non-gaap ep
would
abbott deliv strong result growth revenu report basi
growth organ basi growth due strong advanc
pipelin growth across busi segment
total revenu increas sale grew
organ basi adjust ep ep
 abbott receiv fda approv freestyl libr day sensor
make longest last wearabl glucos sensor avail octob
abbott obtain ce mark freestyl libr system next-gener
product offer option real-tim alarm freestyl libr achiev rapid
market uptak third-quart world-wide sale increas
juli abbott receiv fda approv third-gener version
design advanc simplifi procedur enabl patient
treat mitraclip
septemb abbott announc posit clinic result landmark
coapt studi demonstr minim invas mitraclip heart
valv repair devic improv surviv clinic outcom select patient
function mitral regurgit leaki heart valv result
advanc heart failur coapt studi data submit fda
support consider expand indic mitraclip
ytd stock perform compar
 roa roi roe ttm basi
respect abbott five-year growth forecast compar
 abbott forward price-to-earnings compar
result
growth revenu
report basi
growth organ basi
third-quart
world-wide sale
increas
non- reconcili
non- reconcili
non- reconcili
gross margin increas ttm compar due decreas cog
oper margin increas ttm compar due decreas expens
y/i revenu growth ttm compar
y/i ep growth ttm compar
net margin increas ttm compar due declin tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott vs februari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale abbott vs februari
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale abbott vs februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott vs februari
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free abbott vs februari
current price-to-earnings trade price-to-earnings trail
sinc june due strong growth stock price price-to-earnings
june averag price-to-earnings expect forward price-to-earnings multipl
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust morgan well fargo top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani growth fund america vanguard amcap spdr etf vanguard specialized-health vanguard institut fund-institut vanguard specialized-dividend appreci capit world growth incom abbott vs februari
developmentsnew approv allow chronic pain suffer tri abbott non-opioid pain therapi bee get devic implantnovemb announc launch new drg invis trial approv food drug administr fda receiv ce mark ineurop peopl battl complex chronic pain condit use drg invis trial tri abbott dorsal root ganglion drg stimulationa clinic proven non-opioid treatment option target chronic pain manag patient find adequ pain relief drg therapi abbott proclaim drg system implant empow manag pain familiar consum technolog abbott introduc gener influenza strep assay fastest-ev time molecular resultsoctob announc food drug administr fda clear next-gener influenza strep molecular assay point-of-car test new assay enabl molecular influenza strep result point care current avail id platform formerli aler assay grant clinic laboratori improv amend clia certif waiver abbott heartmat heart fda approv advanc heart failur patient elig heart transplantoctob announc heartmat left ventricular assist devic lvad receiv food drug administr fda approv destin therapi peopl live advanc heart failur approv physician offer heartmat system patient elig transplant live devic rest live one-year result real-world studi show abbott portico transcathet aortic valv safe success reduc sever aortic stenosisseptemb announc one-year result real-world intern multicent studi compani portico transcathet aortic valv replac tavr system patient symptomat sever aortic stenosi life-threaten narrow heart aortic valv one year implant portico valv safe associ low rate stroke death leak patient natur heart tissu portico valv abbott vs februari
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott vs februari
consensu view analyst trend stock
forecast
compar
abbott forward price-to-earnings
compar
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield abbott vs februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr abbott vs februari
stock price volatil quarter gave return period
averag trade volum share period surg
octob
stock price movement show upward trend last one year current trade
stock gave return last one year rang stock
stock price movement shown upward trend gave return past
stock dip januari volatil period
abbott deliv strong perform due continu growth across segment
recommend buy rate abbott tp estim base abt
perform period variou acquisit launch new product
incom statement forecast
non- reconcili
per share item ratio
product perform develop
valuat consensu perform
total revenu increas y/i month perform
upgrad rate buy abbott tp
previous provid upsid potenti
deriv estim base
forward price-to-earnings multipl ep
estim top-lin revenu grow
estim base follow factor strong
growth across segment acquisit aler inc new
product launch quarter strong pipelin
advanc across portfolio
abbott deliv strong result due strong growth across
segment continu develop pipelin total
revenu increas sale grew
organ basi adjust ep
gaap ep
diagnost segment sale grew quarter alin
sell highli differenti instrument achiev
acceler growth strong competit win rate europ
alin instrument placement thu far
come share captur diagnost sale
driven cardiometabol test
establish epd sale led double-digit
growth sever geographi includ russia china
nutrit sale increas quarter led strong
perform intern busi
medic devic sale grew quarter led double-
digit growth electrophysiolog structur heart diabet
compani nameabbott laboratoriestickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth abbott vs februari
diabet anoth area abt technolog
 receiv fda approv sensor
shorter one-hour warmup make libr longest
obtain ce mark freestyl libr system freestyl
libr user across globe
juli us initi pivot trial tendyn devic
design replac damag mitral heart valv without
need open heart surgeri
also receiv fda approv third gener
version mitraclip market lead devic repair
septemb announc result landmark coapt trial
demonstr mitraclip improv surviv clinic
outcom patient function mitral regurgit
preval form condit
current price-to-earnings trade
price-to-earnings trail sinc
june due strong growth stock price price-to-earnings
june averag price-to-earnings
expect forward price-to-earnings multipl
recommend buy rate base month perform
acquisit aler inc strong develop pipelin
across portfolio
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date oct last split factor new per last split date jan inform abbott vs februari
non- reconcili refer page
incom statement item total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli abbott vs februari
 defer incom prepaid current total current net properti plant equiti intang defer incom long-term total non-curr total short-term account tax accru current total current long-term defer tax pension minor long-term total non-curr total addit paid-in retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli abbott vs februari
net cash oper activ period increas due higher segment
oper earn continu improv work capit manag time pension
contribut lower acquisition-rel expens
net cash use invest activ period compar
net cash use financ activ period compar
depreci invest loss stock base chang work account prepaid account incom tax work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt prefer stock common stock dividend financ net cash provid use financ effect exchang rate net chang begin end total revenu increas
compar
increas
rapid diagnost
acquir late last
year therefor
includ organ sale
sale
abbott deliv strong result due strong growth across segment
acquisit aler inc close
total revenu increas compar
organ sale increas net sale growth
exclud impact foreign exchang driven growth
abbott busi segment acquisit aler inc aler close
total revenu increas compar
increas categori reflect growth abbott
diabet busi partial off-set sale abbott medic optic
amo busi johnson johnson double-digit growth diabet
led freestyl libr abbott sensor-bas continu glucos monitor
cgm system remov need routin fingerstick peopl
total revenu increas compar
total intern revenu increas
compar
rapid diagnost acquir late last year therefor
includ organ sale growth result achiev sale
exchang unfavor y/i impact sale
quarter us dollar strengthen versu sever currenc result
larger unfavor impact result quarter
cog increas compar
amort intang asset increas
compar
gross margin increas compar
increas primarili reflect favor comparison versu prior year
includ inventori step-up amort relat st jude medic
acquisit increas also reflect margin improv variou busi
includ diabet cardiovascular neuromodul
 expens increas compar
increas due addit acquir aler
busi well higher spend area cardiovascular
compar
sg expens increas compar
increas due addit acquir aler
busi well higher spend drive continu growth market
expans variou busi partial off-set lower acquisition-rel
gaap ep decreas
compar
total oper incom increas compar
interest expens decreas
compar effect tax rate
compar
net incom decreas compar
non-gaap net incom increas
compar
gaap ep decreas compar
non-gaap ep increas compar
period total revenu increas
compar period total
revenu increas compar
period total intern revenu increas
compar increas
revenu due strong growth across busi segment
period cog increas
compar period amort
intang asset increas compar
period expens increas
compar nine month period expens
cardiovascular neuromodul product segment
diagnost product segment nutrit
product segment establish pharmaceut product
period sg expens increas
compar increas due addit
acquir aler busi well higher spend drive continu growth
market expans variou busi partial off-set lower acquisition-
period oper expens increas
compar period
oper incom compar
period interest expens flat
compar prior-year period effect tax rate declin
compar
period net incom increas
compar period adjust net
incom increas compar
period ep increas
compar period non-gaap ep
increas compar
increas
compar
increas
compar
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic total revenu
report segment increas compar
total revenu increas
compar segment revenu
total revenu follow
decreas
report basi
compar
includ unfavor
effect foreign
sale emerg
market increas due
india china
establish pharmaceut sale decreas report
basi compar includ
unfavor effect foreign exchang total revenu increas
organ basi period total revenu
increas compar
sale growth quarter neg impact comparison
versu sale higher normal due channel
restock across market implement new tax system
total revenu key emerg market establish
pharmaceut product increas
period emerg market establish pharmaceut
product busi includ india russia brazil china along sever
market repres attract long-term growth
opportun abbott brand gener product portfolio sale
emerg market increas due double-digit growth across sever
geographi includ india china
total revenu market increas
period compar
world-wide revenu nutrit product increas
report basi compar
sale includ unfavor effect foreign exchang
increas organ basi
total revenu key
emerg market
increas
period
increas
compar previou
year quarter
total revenu increas
compar previou year quarter period
total revenu increas
total intern revenu increas
compar previou year quarter total intern revenu
increas
world-wide pediatr nutrit revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
organ basi period total revenu increas
compar prior-year period
total revenu increas
compar previou year quarter period
total revenu increas
compar prior-year period
total intern revenu increas report basi
compar previou year quarter
period total revenu increas
compar prior-year period
strong perform quarter led market growth
double-digit growth asia latin america
total revenu increas compar
previou year quarter includ unfavor effect foreign
exchang increas organ basi total revenu
increas compar prior-year period
total revenu declin
compar previou year quarter period total
revenu increas compar
prior-year period
total intern revenu increas report basi
compar previou year quarter
month period total revenu increas
compar prior-year period
total revenu
increas
compar previou
year quarter
compar
previou year
revenu increas
compar
sale perform led strong growth ensur abbott market-
lead complet balanc nutrit brand glucerna abbott
market-lead diabetes-specif nutrit brand sale neg
impact abbott wind non-cor product line
increas
compar
previou year
world-wide diagnost revenu increas
compar revenu increas
organ basi period total revenu increas
compar
diagnost product revenu increas
compar previou year quarter
period total revenu increas
compar prior-year period
diagnost product intern revenu increas
compar previou year quarter
period total intern revenu increas
compar prior-year period
laboratori diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
organ basi period total revenu increas
compar prior-year period
increas
compar previou
year quarter
growth laboratori diagnost revenu quarter
due above-market growth intern total
revenu increas
compar previou year quarter period total
revenu increas compar
previou year quarter
point diagnost
revenu increas
compar
previou year
world-wide molecular diagnost revenu increas
compar previou year quarter world-wide
sale led growth infecti diseas test
period total revenu increas compar
prior-year period
total revenu increas
compar previou year quarter period
total revenu decreas compar
point diagnost
point diagnost revenu increas
compar previou year quarter includ unfavor
effect foreign exchang increas organ basi due
strong intern growth abbott i-stat handheld system
period total revenu increas
compar prior year period
total revenu increas
compar previou year quarter period total
revenu declin
point diagnost
revenu
period
total intern revenu increas
compar previou year quarter period
total intern revenu increas
compar prior-year period
report
basi
compar
previou year
diagnost revenu
month period total revenu
period total intern
revenu
period increas led cardiometabol test
world-wide medic devic sale increas report basi
compar previou year quarter
organ basi sale increas period total
revenu increas compar prior-
year period
medic devic revenu increas
compar previou year quarter
period total revenu increas
compar prior-year period
medic devic intern revenu increas
compar previou year quarter
period total intern revenu increas
compar prior-year period
cardiovascular neuromodul
cardiovascular neuromodul revenu increas
compar previou year quarter
month period total revenu increas
compar prior-year period
electrophysiolog revenu increas
compar previou year quarter period
total revenu increas total revenu
 increas total intern
revenu increas growth led
strong perform cardiac map ablat cathet well
strong growth abbott confirm rxtm insert cardiac monitor icm
structur heart revenu increas
compar previou year quarter period total
revenu increas total revenu
 increas total intern revenu
increas growth structur heart
driven sever product area across abbott broad portfolio includ
amplatzertm pfo occlud mitraclip abbott market-lead devic
minim invas treatment mitral regurgit
diabet revenu increas
compar previou year quarter period total
revenu increas compar prior-year
period total revenu increas
compar previou year quarter total intern revenu
increas compar previou year
quarter growth led rapid market uptak freestyl libr
cardiovascular
revenu increas
compar
previou year
revenu increas
compar
previou year
 fda approv
minim invas
obtain ce mark
juli abbott receiv fda approv third-gener version
minim invas mitraclip heart valv repair devic new version
includ design advanc simplifi procedur enabl
patient treat mitraclip
septemb abbott announc posit clinic result landmark
coapt studi demonstr mitraclip improv surviv
clinic outcom select patient function mitral regurgit
coapt studi data submit fda support consider
expand indic mitraclip
quarter abbott receiv fda approv freestyl libr
day sensor longest last glucos wearabl sensor avail
octob abbott obtain ce mark freestyl libr system next-
octob abbott announc heartmat left ventricular assist
devic lvad receiv fda approv destin therapi
peopl live advanc heart failur approv physician
offer heartmat system patient elig transplant
live devic rest live
novemb abbott announc launch new drg invis trial
approv fda receiv ce mark europ
patient find adequ pain relief drg therapi
abbott proclaim drg system implant empow
manag pain familiar consum technolog
abbott project adjust ep
ep
abbott expect organ sale growth rang expect
adjust gross margin ratio sale adjust
sale adjust sg expens sale
abbott forecast net specifi item per share
expens charg associ cost reduct initi
expect ep non-gaap ep
would
abbott forecast specifi item primarili relat
intang amort acquisition-rel expens cost reduct
initi expens
adjust ep
ep
non-gaap ep
would
abbott deliv strong result growth revenu report basi
growth organ basi growth due strong advanc
pipelin growth across busi segment
total revenu increas sale grew
organ basi adjust ep ep
 abbott receiv fda approv freestyl libr day sensor
make longest last wearabl glucos sensor avail octob
abbott obtain ce mark freestyl libr system next-gener
product offer option real-tim alarm freestyl libr achiev rapid
market uptak third-quart world-wide sale increas
juli abbott receiv fda approv third-gener version
design advanc simplifi procedur enabl patient
treat mitraclip
septemb abbott announc posit clinic result landmark
coapt studi demonstr minim invas mitraclip heart
valv repair devic improv surviv clinic outcom select patient
function mitral regurgit leaki heart valv result
advanc heart failur coapt studi data submit fda
support consider expand indic mitraclip
ytd stock perform compar
 roa roi roe ttm basi
respect abbott five-year growth forecast compar
 abbott forward price-to-earnings compar
result
growth revenu
report basi
growth organ basi
third-quart
world-wide sale
increas
non- reconcili
non- reconcili
non- reconcili
gross margin increas ttm compar due decreas cog
oper margin increas ttm compar due decreas expens
y/i revenu growth ttm compar
y/i ep growth ttm compar
net margin increas ttm compar due declin tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott vs februari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale abbott vs februari
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale abbott vs februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott vs februari
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free abbott vs februari
current price-to-earnings trade price-to-earnings trail
sinc june due strong growth stock price price-to-earnings
june averag price-to-earnings expect forward price-to-earnings multipl
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust morgan well fargo top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani growth fund america vanguard amcap spdr etf vanguard specialized-health vanguard institut fund-institut vanguard specialized-dividend appreci capit world growth incom abbott vs februari
developmentsnew approv allow chronic pain suffer tri abbott non-opioid pain therapi bee get devic implantnovemb announc launch new drg invis trial approv food drug administr fda receiv ce mark ineurop peopl battl complex chronic pain condit use drg invis trial tri abbott dorsal root ganglion drg stimulationa clinic proven non-opioid treatment option target chronic pain manag patient find adequ pain relief drg therapi abbott proclaim drg system implant empow manag pain familiar consum technolog abbott introduc gener influenza strep assay fastest-ev time molecular resultsoctob announc food drug administr fda clear next-gener influenza strep molecular assay point-of-car test new assay enabl molecular influenza strep result point care current avail id platform formerli aler assay grant clinic laboratori improv amend clia certif waiver abbott heartmat heart fda approv advanc heart failur patient elig heart transplantoctob announc heartmat left ventricular assist devic lvad receiv food drug administr fda approv destin therapi peopl live advanc heart failur approv physician offer heartmat system patient elig transplant live devic rest live one-year result real-world studi show abbott portico transcathet aortic valv safe success reduc sever aortic stenosisseptemb announc one-year result real-world intern multicent studi compani portico transcathet aortic valv replac tavr system patient symptomat sever aortic stenosi life-threaten narrow heart aortic valv one year implant portico valv safe associ low rate stroke death leak patient natur heart tissu portico valv abbott vs februari
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott vs februari
consensu view analyst trend stock
forecast
compar
abbott forward price-to-earnings
compar
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield abbott vs februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr abbott vs februari
stock price volatil quarter gave return period
averag trade volum share period surg
octob
stock price movement show upward trend last one year current trade
stock gave return last one year rang stock
stock price movement shown upward trend gave return past
stock dip januari volatil period
abbott deliv strong perform due continu growth across segment
recommend buy rate abbott tp estim base abt
perform period variou acquisit launch new product
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
